|
The CLX Laser
CLX · Submental laser
A precise, non-thermal approach to the submental area.
Two wavelengths, one focused aesthetic platform — touchless, non-thermal, no downtime.
CLX pairs 520 nm green and 405 nm violet in one high-energy, non-thermal laser platform for non-invasive aesthetic treatment to improve the appearance of the submental (under-chin) area. The treatment is delivered without contact and without therapeutic heating, so the patient rests comfortably while the device operates. For the clinic it is a streamlined model: no needles, no incisions, and no applicator cards or consumable kits to restock.
- 520 nm green
- 405 nm violet
- Touchless
- Non-thermal
- 15-minute sessions
- FDA-cleared
The snatched jawline, non-surgicallyCleared for non-invasive aesthetic treatment to improve the appearance of the submental area — eight 15-minute, non-contact sessions over four weeks.
86.7%
blinded-review success in the dual-center clinical study
92%
patient satisfaction at 12 weeks
0
device-related adverse events
15 min
per session · 8 sessions over 4 weeks · no downtime
Our fat-loss lasers have been featured in
How CLX works
High-energy, not high-powered.
Built around the energy carried by each photon and the biological response to an appropriate light dose — not around wattage and heat.
CLX delivers specific green and violet wavelengths to the submental area through a non-thermal, non-contact approach. In the clinical study, the mechanism is described as stimulating adipocytes to release stored lipid content without destroying the cell; released lipids are processed naturally by the body, and the appearance of the submental area changes over the treatment course. The patient rests comfortably for 15 minutes while the device operates — no needles, no incisions, no anesthesia, and a walk-in, walk-out experience with no procedural downtime.
| CLX | Injectables and surgical options | |
|---|---|---|
| Contact | Non-contact, non-thermal | Needles, incisions or anesthesia |
| Session | 15 minutes, hands-free, patient resting | Procedure time plus recovery |
| Downtime | None — walk in, walk out | Swelling, bruising, days to weeks |
| Consumables | None — no syringes, gels or applicator cards | Per-treatment product and kit costs |
Touchless. Non-thermal. No downtime. Built on Erchonia laser science.
Why clinics choose it
Why clinics add CLX
A high-demand, cash-pay treatment with premium pricing and no per-session consumables.
01
High-demand, cash-pay
The snatched jawline is one of the most requested aesthetic looks right now. CLX puts a non-surgical answer in your clinic before competitors do.
02
Premium pricing, no consumables
Strong margins on every session — no needles, no syringes, no gels to reorder. Package pricing is easy to build and easy to sell.
03
FDA-cleared credibility
Non-invasive, no downtime and FDA-cleared — a combination that converts skeptical patients and takes liability concerns out of the conversation.
FDA indications for use
Indications for use (FDA-cleared)
The Erchonia® CLX laser is indicated for:
- Non-invasive aesthetic treatment to improve the appearance of the submental (under-chin) area
Prescription use (21 CFR 801 Subpart D). Intended for medical professionals.
Clinical evidence
Eight sessions. Blinded review.
A prospective, dual-center clinical study in adults with measurable submental fat — eight 15-minute, non-contact treatments over four weeks, judged by three independent, board-certified cosmetic surgeons in a blinded review.
86.7%
blinded-review success on an intent-to-treat basis — and 95.8% correct identification of the post-treatment photograph at the 12-week follow-up.
Intent-to-treat: 86.7%; per-protocol at 12 weeks: 95.8%. Erchonia CLX dual-center clinical study.
5.45 mm
mean reduction in submental skinfold thickness, with BMI stable — the change is under the chin, not on the scale.
Erchonia CLX dual-center clinical study. Individual results vary.
92%
patient satisfaction at 12 weeks, with zero device-related adverse events.
Erchonia CLX dual-center clinical study.
Photographs from the CLX clinical study. Individual results vary. CLX is cleared for non-invasive aesthetic treatment to improve the appearance of the submental area.
Where it works
Where CLX fits
A focused service line for the aesthetic room.
01
Aesthetic practices and med spas
A non-surgical submental option that slots into an existing aesthetic service mix, package-priced, with no consumables.
02
Dental and facial aesthetics
“Teeth whitening. Jaw tightening.” — the under-chin add-on for practices already treating the face.
03
Body-contouring clinics
The third platform beside the Zerona VZ8 and Emerald — the patient whose priority is the jawline, not the waist.
Clinic · Patients · P&L
See the numbers for your practice.
Project revenue impact, break-even timelines and per-visit value increases from your own clinic volume.
Cash-pay economics
Contouring is an elective, package-priced service — revenue that doesn’t run through a payer.
Session economics you can price in your head
No applicator cards, no per-cycle consumable kits — the margin on every session stays in the practice.
Hands-free, high-throughput delivery
Unattended protocols multiply what one room and one staff member can produce in a day.
The line
Compare the fat-loss lasers
Full-body or higher-BMI — two cleared platforms for the contouring room.
Zerona VZ8
Body contouring · hands-free · 2× faster
The classic contouring platform for targeted inch loss — the most energetic fat-loss laser on the market, at half the per-session time of the original Zerona.
Emerald
Circumference reduction · BMI up to 40
The higher-BMI platform — cleared for circumference reduction in patients with a BMI up to 40, the population most contouring devices exclude.
Next step
Put the non-surgical jawline in your clinic.
Aesthetic practice, med spa or dental office — tell us how it runs.
Every system ships with onboarding and protocol support from our clinical team.